Director/PDMR Shareholding

Haleon PLC

24 March 2026

 

​Haleon plc: Director/PDMR Shareholding 

24 March 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").

This notification sets out the details of the vesting of Haleon share awards over ordinary shares made to a PDMR in March 2023 under the Haleon Performance Share Plan and Deferred Annual Bonus Plan and the subsequent sale of ordinary shares to meet tax liabilities.

On 23 March 2026, Brian McNamara, Chief Executive Officer, received the vesting of awards of Haleon ordinary shares under the Haleon Performance Share Plan and Deferred Annual Bonus Plan. Vesting under both plans included dividends accrued.

The award under the Performance Share Plan was conditional on continued employment and on the satisfaction of the performance conditions over the performance period ended on 31 December 2025 approved by the Remuneration Committee, which (after tax on the gross award) must be retained until the shareholding requirement is met, and in any event for Executive Directors two years after receipt.

Performance targets and levels of achievement are disclosed in the 2025 Annual Report and 20-F. The awards are subject to malus and clawback provisions.

1	Details of the issuer or emission allowance market participant
a)	Name of the entity	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment to prior notifications	Initial Notification
3	Details of the person discharging managerial responsibilities / person closely associated ("PCA")
a)	PDMR/PCA	PDMR
b)	Name	Brian McNamara
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of Instrument	Share
	Identification code	GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares in respect of the Haleon plc Performance Share Plan.
c)	Currency, Price(s) and Volume(s)
				Price(s)	Volume(s)
				Nil	1,497,695.24
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	23 March 2026
f)	Place of the transaction	Outside a trading venue
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of Instrument	Share
	Identification code	GB00BMX86B70
b)	Nature of the transaction	Automatic disposal of Ordinary Shares resulting from Haleon plc Performance Share Plan vesting to cover tax liabilities.
c)	Currency, Price(s) and Volume(s)
				Price(s)	Volume(s)
				£3.684419	704,974.22
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	23 March 2026
f)	Place of the transaction	London Stock Exchange (XLON)
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of Instrument	Share
	Identification code	GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares in respect of the Haleon plc Deferred Annual Bonus Plan.
c)	Currency, Price(s) and Volume(s)
				Price(s)	Volume(s)
				Nil	133,733.56
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	23 March 2026
f)	Place of the transaction	Outside a trading venue
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of Instrument	Share
	Identification code	GB00BMX86B70
b)	Nature of the transaction	Automatic disposal of Ordinary Shares resulting from Haleon plc Deferred Annual Bonus Plan vesting to cover tax liabilities.
c)	Currency, Price(s) and Volume(s)
				Price(s)	Volume(s)
				£3.684419	63,012.31
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	23 March 2026
f)	Place of the transaction	London Stock Exchange (XLON)

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visit www.haleon.com. 

 

END